The firm will offer up to 12,030,218 common shares for Keystone Capital Partners to sell and is expecting to net around $2.1 million in gross proceeds.

The foundation hopes to put the funds toward two clinical programs in blood cancers and one preclinical project in solid tumors.

The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.

News items for the week of Feb. 10, 2025.

The collaboration will involve making a real-world multimodal dataset available in Tempus' Lens platform that researchers can use to accelerate treatment development.

In the deal, GenomOncology will integrate Pillar's RUO NGS panels into its clinical decision support platform to enable personalized cancer treatment insights.

The move will provide funds to advance ETX101, a gene therapy the company is developing for SCN1A-positive Dravet syndrome, among other programs.

The firm will study its autologous cell therapy alone and in combination with Eisai's Lenvima in patients with hepatitis B-driven hepatocellular carcinoma.

The Phase II/III trial will include patients with PD-L1-positive tumors and who are HPV-negative.

ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.